Table 5.
Association between genetic factors and pain intensity (PI) outcomes before and after opioid treatment.
| PIt0 | ΔVAS | Responders | Timetot | |||||
|---|---|---|---|---|---|---|---|---|
| n >4/≤4 |
OR (95% CI) | n >2/≤2 |
OR (95% CI) | n No/Yes |
OR (95% CI) | Mean ± SD Median (IQ Range) |
p-Value | |
| IL-6 rs1800795 | ||||||||
| Co-dominant | ||||||||
| C/C | 4/5 | 1 | 5/4 | 1 | 0/9 | 1 | 107.22 ± 49.246 118.00 (96.00–133.00) |
0.290 ** 0.235 † |
| G/C | 12/18 | 0.51 (0.075–3.497) | 15/15 | 1.19 (0.232–6.145) | 10/20 | 0.61 (0.149–2.485) | 144.45 ± 68.914 148.50 (78.00–201.00) |
|
| G/G | 18/17 | 2.97 (0.356–24.804) | 6/29 | 5.44 (0.881–33.646) | 9/26 | - | 143.76 ± 65.459 138.00 (102.00–191.50) |
|
| Dominant | ||||||||
| C/C | 4/5 | 1 | 5/4 | 1 | 0/9 | 1 | 107.22 ± 49.246 118.00 (96.00–133.00) |
0.114 ** 0.092 † |
| G/C + G/G | 30/35 | 0.97 (0.161–5.855) | 21/44 | 2.15 (0.447–10.312) | 19/46 | - | 144.08 ± 66.546 144.00 (100.00–192.00) |
|
| Recessive | ||||||||
| C/C + G/C | 16/23 | 1 | 20/19 | 1 | 10/29 | 1 | 135.86 ± 66.237 133.00 (78.00–192.00) |
0.608 ** 0.697 † |
| G/G | 18/17 | 5.00 (1.105–22.651) | 6/29 | 4.75 (1.271–17.785) | 9/26 | 0.95 (0.250–3.604) | 143.76 ± 65.459 138.00 (102.00–191.50) |
|
| IL-6 rs1800796 | ||||||||
| Co-dominant | ||||||||
| G/C | 3/8 | 1 | 4/7 | 1 | 3/8 | 1 | 152.23 ± 69.778 150.00 (100.00–192.00) |
0.492 ** 0.584 † |
| G/G | 31/32 | 3.73 (0.502–27.708) | 22/41 | 0.65 (0.145–2.944) | 16/47 | 0.90 (0.165–4.969) | 137.39 ± 65.106 133.00 (99.00–192.00) |
|
| IL-6 rs1800797 | ||||||||
| Co-dominant | ||||||||
| A/A | 3/5 | 1 | 4/4 | 1 | 1/7 | 1 | 141.78 ± 64.620 133.00 (102.00–185.50) |
0.648 ** 0.660 † |
| A/G | 10/19 | 0.35 (0.043–2.854) | 16/13 | 0.59 (0.105–3.380) | 8/21 | 0.19 (0.167–2.185) | 142.48 ± 68.160 147.00 (96.00–192.00) |
|
| G/G | 21/16 | 3.30 (0.665–17.255) | 6/31 | 3.75 (0.586–24.049) | 10/27 | 0.22 (0.020–2.550) | 119.00 ± 64.73 119.00 (68.50–163.25) |
|
| Dominant | ||||||||
| A/A | 3/5 | 1 | 22/44 | 1 | 18/48 | 1 | 142.09 ± 65.682 141.00 (100.00–192.00) |
0.350 ** 0.365 † |
| G/G + A/G | 31/35 | 1.06 (0.161–7.016) | 4/4 | 0.78 (0.150–4.009) | 1/7 | 4.84 (0.475–49.223) | 119.00 ± 64.73 119.00 (68.50–163.25) |
|
| Recessive | ||||||||
| G/G | 21/16 | 1 | 6/31 | 1 | 10/27 | 1 | 141.78 ± 64.620 133.00 (102.00–185.50) |
0.776 ** 0.833 † |
| A/G + A/A | 13/24 | 0.14 (0.030–0.621) | 20/17 | 0.18 (0.048–0.668) | 9/28 | 1.27 (0.322–5.018) | 137.40 ± 67.263 134.50 (96.00–192.00) |
|
| IL-8 rs 4073 | ||||||||
| Co-dominant | ||||||||
| A/A | 10/10 | 1 | 6/14 | 1 | 4/16 | 1 | 135.55 ± 83.109 128.50 (74.50–199.00) |
0.770 ** 0.832 † |
| A/T | 14/16 | 1.31 (0.291–5.924) | 9/21 | 1.08 (0.273–4.263) | 8/22 | 0.73 (0.150–3.529) | 135.85 ± 56.42 136.25 (100.00–189.50) |
|
| T/T | 10/14 | 1.00 (0.213–4.719) | 11/13 | 0.48 (0.111–2.043) | 7/17 | 0.55 (0.101–2.972) | 147.65 ± 61.751 147.00 (101.50–191.75) |
|
| Dominant | ||||||||
| A/A | 10/10 | 1 | 6/14 | 1 | 4/16 | 1 | 135.55 ± 83.109 128.50 (74.50–199.00) |
0.749 ** 0.794 † |
| A/T + T/T | 24/30 | 1.16 (0.300–4.472) | 20/34 | 0.77 (0.221–2.700) | 15/39 | 0.65 (0.149–2.834) | 141.02 ± 58.580 141.00 (100.00–191.50) |
|
| Recessive | ||||||||
| A/A + A/T | 24/26 | 1 | 15/35 | 1 | 12/38 | 1 | 135.73 ± 67.545 133.00 (99.00–192.00) |
0.468 ** 0.544 † |
| T/T | 10/14 | 0.85 (0.239–3.041) | 11/13 | 0.45 (0.143–1.436) | 7/17 | 0.67 (0.179–2.538) | 147.65 ± 61.751 147.00 (101.50–191.75) |
|
| TNFα rs1800629 | ||||||||
| Co-dominant | ||||||||
| A/G | 5/6 | 1 | 3/8 | 1 | 4/7 | 1 | 119.54 ± 87.222 118.00 (59.00–130.00) |
0.274 ** 0.095 † |
| G/G | 29/34 | 0.93 (0.151–5.696) | 23/40 | 0.45 (0.091–2.244) | 15/48 | 1.32 (0.282–6.142) | 143.09 ± 61.21 144.00 (101.00–192.00) |
|
** ANOVA, analysis adjusted for: age class, gender, Pit0, diagnosis, metastasis. † Kruskal–Wallis test.